Amundi Asset Management US’s CRISPR Therapeutics CRSP Stock Holding History

Amundi Asset Management US’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$679K	Buy	5,570 +70	+1%	+$10.6K	﹤0.01%	1295
2020 Q4	$842K	Hold	5,500	–	–	﹤0.01%	1241
2020 Q3	$460K	Hold	5,500	–	–	﹤0.01%	1267
2020 Q2	$404K	Hold	5,500	–	–	﹤0.01%	1278
2020 Q1	$233K	Hold	5,500	–	–	﹤0.01%	1305
2019 Q4	$335K	Hold	5,500	–	–	﹤0.01%	1383
2019 Q3	$225K	Buy	5,500 +1,200	+28%	+$57.3K	﹤0.01%	1433
2019 Q2	$203K	Hold	4,300	–	–	﹤0.01%	1475
2019 Q1	$154K	Sell	4,300 -100	-2%	-$3.46K	﹤0.01%	1483
2018 Q4	$126	Buy	4,400 +1,200	+38%	+$41.7K	﹤0.01%	1468
2018 Q3	$142K	Hold	3,200	–	–	﹤0.01%	1488
2018 Q2	$188K	Buy	3,200 +400	+14%	+$22.8K	﹤0.01%	1428
2018 Q1	$128K	Sell	2,800 -400	-13%	-$16.5K	﹤0.01%	1383
2017 Q4	$75K	Buy	+3,200	New	+$60.8K	﹤0.01%	1455

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Amundi Asset Management US's CRSP Position: Q1 2021 in Review

Amundi Asset Management US increased its CRISPR Therapeutics (CRSP) stake by 1.3% in Q1 2021, buying an estimated $10.6K and bringing the position to 5,570 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Amundi Asset Management US first reported a position in CRSP in Q4 2017 and has held it in 14 quarters since. The position peaked at $842K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

Amundi Asset Management US held 5,570 shares of CRISPR Therapeutics worth $679K as of Q1 2021.
Amundi Asset Management US bought 70 CRISPR Therapeutics shares in Q1 2021, an estimated $10.6K.
CRISPR Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1295 holding.
Amundi Asset Management US first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 14 quarters since.
Amundi Asset Management US's CRISPR Therapeutics position peaked at $842K in Q4 2020.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.